EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS ),
a Boston-based biopharmaceutical company focused on the global
development and commercialization of biosimilar monoclonal antibodies,
today provided a corporate update and reported financial results for the
third quarter ended September 30, 2014.
Sign-up for Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.